2023 World Conference on Lung Cancer (Posters)-P2.17. EFfectiveness and Safety Profile of Lurbinectedin in Second-Line Small Cell Lung Cancer: A Real-World Study

P2.17. EFfectiveness and Safety Profile of Lurbinectedin in Second-Line Small Cell Lung Cancer: A Real-World Study - PDF(Slides)

Back to course

Pdf Summary

A real-world study evaluated the effectiveness and safety profile of lurbinectedin as a second-line treatment for small cell lung cancer (SCLC). Lurbinectedin received accelerated approval from the FDA in 2020 based on promising results from a phase 2 trial. The study assessed real-world effectiveness outcomes, including response rates and progression-free survival, as well as adverse events of special interest, such as neutropenia, thrombocytopenia, anemia, and febrile neutropenia.<br /><br />The effectiveness cohort included 374 patients who received lurbinectedin as second-line therapy. The median real-world progression-free survival was 2.5 months, and the median time to next treatment was 3.6 months. The median real-world duration of response was 2.7 months. The response rates were consistent with those observed in the phase 2 trial, but the progression-free survival and duration of response were slightly lower. <br /><br />The most common adverse events in the real-world cohort were hematologic toxicities, including neutropenia, leukopenia, anemia, thrombocytopenia, and febrile neutropenia. The rates of these adverse events tended to be lower than those observed in the phase 2 trial, possibly due to the use of prophylactic granulocyte colony-stimulating factors (G-CSF) in the real-world setting. <br /><br />The study was limited by its retrospective and observational nature, as well as missing data. However, the findings suggest that lurbinectedin is effective and well-tolerated in the second-line treatment of SCLC in a real-world setting, with outcomes generally consistent with those observed in the phase 2 trial. The use of G-CSF may contribute to lower rates of certain adverse events. Further research is needed to validate these findings and explore other factors that may impact the effectiveness and safety profile of lurbinectedin in SCLC.

Asset Subtitle

Apar Kishor Ganti

Meta Tag

Speaker Apar Kishor Ganti

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

lurbinectedin

small cell lung cancer

SCLC

effectiveness

safety profile

accelerated approval

phase 2 trial

real-world study

adverse events

progression-free survival